Publications by authors named "Olivia Golan"
Aims: To understand how the US public defines recovery from opioid misuse and the recovery-related resources it views as most helpful, and to compare differences by opioid misuse history and demographic characteristics.
Design: Observational study of data from the nationally representative AmeriSpeak® Panel survey administered in October/November 2021.
Setting: United States.
Background: To promote parent-child reunification, family dependency drug courts (FDDCs) facilitate substance use disorder treatment for people whose children have been removed due to parental substance use. The COVID-19 pandemic disrupted FDDC operations, forcing FDDCs to quickly adapt to new circumstances. Although existing research has examined COVID-19 impacts on adult drug courts and civil dependency courts, studies have yet to examine the impact of COVID-19 on FDDCs specifically.
View Article and Find Full Text PDFBackground: Buprenorphine is among the most effective treatments for opioid use disorder. Even though the federal government recently eliminated the waiver requirement and patient limits applicable to office-based buprenorphine treatment (OBBT), among other settings, some states may still have policies imposing requirements on OBBT providers not required by federal law.
Methods: We collected statutes and regulations from 50 US states and the District of Columbia (ie, 51 jurisdictions) between August 11 and November 30, 2022 using the Nexis Uni legal database and search terms related to OBBT counseling, dosage, and/or frequency of visits.
Article Synopsis
- The study investigates how the Medicaid expansion under the Affordable Care Act affected buprenorphine initiation rates for treating opioid use disorder, especially focusing on county income levels and rural-urban status.
- Researchers analyzed data from 2009 to 2018 and found that while urban counties with lower median incomes saw significantly increased buprenorphine use post-expansion, rural counties did not experience similar benefits linked to income levels.
- The conclusion emphasizes the need for future policies to specifically address buprenorphine access challenges in low-income rural areas, as Medicaid expansion did not reduce disparities for these communities.
Background: The COVID-19 pandemic led several states to adopt policies permitting the delivery of substance use disorder treatment (SUDT) by telehealth. We assess the impact of state-level telehealth policies in 2020 that specifically permitted audio or audiovisual forms of telehealth offerings among SUDT facilities.
Procedure: Cross-sectional analysis of secondary data from between 2019 and 2022.
Introduction: Person-centered care (PCC) is an ethical imperative with eight domains, but operation of some PCC domains in substance use disorder (SUD) treatment has been underexplored.
Objective: We sought to identify strategies for operationalizing eight PCC domains in SUD treatment facilities and themes across these strategies.
Methods: We recruited 36 clients and staff from a large publicly funded behavioral health system for individual, semi-structured qualitative interviews.
Background: While person-centered care (PCC) includes multiple domains, residential substance use disorder (SUD) treatment clients may value certain domains over others. We sought to identify the PCC domains most valued by former residential SUD treatment clients. We also sought to explore conceptual distinctions between potential theoretical PCC subdomains.
View Article and Find Full Text PDFImportance: Expanding the use of buprenorphine for treating opioid use disorder is a critical component of the US response to the opioid crisis, but few studies have examined how state policies are associated with buprenorphine dispensing.
Objective: To examine the association of 6 selected state policies with the rate of individuals receiving buprenorphine per 1000 county residents.
Design, Setting, And Participants: This cross-sectional study used 2006 to 2018 US retail pharmacy claims data for individuals dispensed buprenorphine formulations indicated for treating opioid use disorder.
Research Objective: Medications for opioid use disorder (MOUDs) - including methadone, buprenorphine, and naltrexone - are the most effective treatments for opioid use disorder (OUD). Historically, insurers have required prior authorization for MOUD, but prior authorization is often reported as a key barrier to MOUD prescribing. Some states have passed laws prohibiting MOUD prior authorization requirements.
View Article and Find Full Text PDFBackground: People with opioid use disorder (OUD) experience lower quality of life (QoL) than the general population, but buprenorphine treatment for OUD could help improve QoL of individuals with OUD. Thus, we conducted a systematic review and meta-analysis of the impact of buprenorphine on QoL among people with OUD.
Methods: Seven databases were searched through August 2020.